Andrew T. Kaplan bought $134.4M of Kailera Therapeutics (KLRA)

Executed Apr 20, disclosed Apr 20, the same day.

Value, as filed

$134.4M

8,398,438 sh × $16.00

Executed

Apr 20

the trade date, as filed

Disclosed

Apr 20

0 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

-26.2%

-26.2% from execution

Over the 21 trading sessions from the disclosed entry session (Apr 20), the stock returned -26.2% (delay-adjusted); from the execution session (Apr 20), -26.2%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

AK Andrew T. Kaplan Director profile →

Andrew T. Kaplan (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in KLRA. Across 1 priced purchase filing, the average 21-session return was -26.2% from execution and -26.2% from disclosure (delay-adjusted; derived). The largest single filing was $134.4M of KLRA (8,398,438 sh × $16.00, as filed), executed Apr 20.

The name

KLRA KLRA KLRA · 5 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→